Pharmaceuticals
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including$420 million in near-term milestone payments and opt-in right for solid tumors – – Companies to jointly develop and commercialize ziftomenib; 50/50 profit share in the U.S.; Kura to lead...
2024-11-21 06:00
1033
GBI Biomanufacturing Expands Capabilities with Automated Aseptic Fill-Finish for Drug Products
PLANTATION, Fla., Nov. 21, 2024 /PRNewswire/ -- GBI Biomanufacturing (GBI), one of the world's longest serving contract development and manufacturing organizations (CDMO), is pleased to announce the expansion of its Drug Product (DP)services, to include automated sterile fill and finish capabilit...
2024-11-21 01:00
703
Samsung Biologics signs manufacturing deal with European pharmaceutical company
* The company will provide manufacturing services through 2031 in deals worth overUSD 668 million * Samsung Biologics' cumulative contract value for 2024 surpasses USD 4 billion with latest deals INCHEON, South Korea, Nov. 20, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global ...
2024-11-20 07:23
1104
Say Hello to 3.0: Datarithm Releases Latest Version of Inventory Management Solution
SYRACUSE, N.Y., Nov. 19, 2024 /PRNewswire/ -- In a landscape marked by intense competition, rising costs, and stringent regulatory requirements, independent pharmacies face an array of challenges that threaten their viability and success. Today, Datarithm® is proud to announce a solution to these...
2024-11-19 22:00
821
Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA
48-week end-of-treatment data from the ongoing Phase 2 ENSURE study clearly demonstrated the added benefits of elebsiran towards achieving a higher functional cure rate in combination with PEG-IFNα Data from multiple combination studies sponsored by the Company and its partner continue to suppor...
2024-11-19 19:30
1497
Everest Medicines Announces NEFECON® Has Received Full Approval from South Korea's Ministry of Food and Drug Safety (MFDS) for the Treatment of Primary IgA Nephropathy
SHANGHAI, Nov. 19, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that NEFECON® has received full appro...
2024-11-19 07:40
1327
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
MELBOURNE, Australia, Nov. 19, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces it will expand its theranostic pipeline with new assets targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nucl...
2024-11-19 06:24
1404
VelaVigo Announces Exclusive Option Agreement with Avenzo to License a Potential First-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate
SHANGHAI and BOSTON, Nov. 18, 2024 /PRNewswire/ -- VelaVigo Cayman Limited (VelaVigo), a biotech company focusing on discovery and development of multi-specific antibodies and antibody-drug conjugates (ADC), today announced it has entered into an agreement with Avenzo Therapeutics, Inc. (Avenzo)...
2024-11-18 21:01
1159
New Report from Clarivate and Healthcare Executive Explores Mainland China's Biopharma Revolution and Increasing Global Influence
New report analyses Mainland China's transformation into a global biopharma powerhouse, with key insights for international stakeholders LONDON, Nov. 18, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, in partnership withHealthcare Executi...
2024-11-18 16:00
1160
Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions
* Single dose of RN0191 achieved up to 95% individual maximum and 87% mean maximum PCSK9 reduction, and up to 74% individual maximum and 56% mean maximal LDL-C lowering * Robust and sustainable treatment effects support at least bi-annual dosing regimen * Best-in-class potential of novel PC...
2024-11-18 09:00
1687
Boehringer Ingelheim Commits to Veeva Vault CRM
Top biopharma company selects the next generation of CRM for life sciences as
its commercial foundation for future expansion and launches
SINGAPORE, Nov. 18, 2024 /PRNewswire/ -- Veeva Systems
2024-11-18 09:00
1117
Ascentage Pharma Announces a New Drug Application for Its Novel Bcl-2 Inhibitor Lisaftoclax Accepted and Recommended Priority Review Designation by CDE of China NMPA
ROCKVILLE, Md. and SUZHOU, China, Nov. 17, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that a New Drug Applica...
2024-11-17 22:24
1448
SEKISUI Completes £15.7 Million Expansion in cGMP Biopharma CDMO Capacity
Growth of UK facility will enable clinical-grade manufacturing of drug substances for range of biopharmaceutical products BURLINGTON, Mass., Nov. 15, 2024 /PRNewswire/ -- SEKISUI Diagnostics' microbial CDMO business announces it has completed construction of its £15.7 million ($20.7 million) cGM...
2024-11-14 23:45
830
Continuity Biosciences Launches to Enable Breakthrough Therapies with Innovative Delivery Technologies
BRADENTON, Fla. and HOUSTON, Nov. 13, 2024 /PRNewswire/ -- Continuity Biosciences, LLC, a new bioscience company dedicated to developing and commercializing cutting-edge technologies for cell reprogramming, immune modulation, and drug delivery, is excited to announce its official launch. The com...
2024-11-13 20:30
1180
Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology
MELBOURNE, Australia and BERLIN, Germany, Nov. 13, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a technology collaboration and licence agreement withBerlin -based Eckert & Ziegler SE (EZAG) for the use of EZAG's cyclotro...
2024-11-13 16:18
1467
Caliway Announced EMA Orphan Drug Designation Granted to CBL-514 for Dercum's Disease Treatment
- CBL-514 is the first and only drug to receive EMA Orphan Drug Designation for Dercum's disease treatment. - CBL-514 received both FDA Orphan Drug Designation and Fast Track designation for Dercum's disease treatment earlier this year. - CBL-514 Phase 2 study for Dercum's disease showed that it c...
2024-11-13 13:36
1116
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
-Phase III trial enrolled a total of 480 patients with moderate to severe acne -Topline results expected in the second quarter 2025 HANGZHOU, China, Nov. 12, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces completion of enrollment of 480 patients for Phase III c...
2024-11-12 19:30
1348
Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks
* After two weeks of treatment, GZR18 tablets resulted in an average weight reduction of up to 4.16%, with continued weight loss observed even after discontinuation. * The pharmacokinetic profile supports a once-daily oral dosing regimen for GZR18 tablets. * The safety and tolerability of G...
2024-11-12 19:00
1151
World's First Patent Acquired for Animal Supplement "Pinfenon" (S) (R)
- Patent Covers Invention of Treatment Drug and Prophylactic Drug for Lowering Cardiac Disorder Markers in Dogs as Well as Their Manufacturing Methods - TOKYO, Nov. 12, 2024 /PRNewswire/ -- Scarecrow Incorporated, based in Tokyo's Shibuya Ward, is pleased to announce that it has acquired the worl...
2024-11-12 14:00
1180
Economist Impact's 4th edition Future of Health Asia to empower healthcare stakeholders by building strategies for a sustainable healthcare system, and igniting investment for an inclusive and healthier future
Members of the media are invited to register here
2024-11-11 20:56
1763
Week's Top Stories
Most Reposted
Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 304 media titles]
2024-11-20 13:29Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 297 media titles]
2024-11-20 16:30
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
[Picked up by 296 media titles]
2024-11-15 15:25
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 282 media titles]
2024-11-20 09:00
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8669
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5220
Yingli Solar's Global Product Workshops Launched in Malaysia
2024-11-15 21:40
4613
